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Abstract 
Introduction: HIV infection is considered a risk factor for severe outcomes of influenza A(H1N1)v infection. However, data on immune 
response against influenza A(H1N1)v virus in HIV-infected patients are lacking.  
Methodology: Data from seven HIV-positive and 14 HIV-negative patients infected with A(H1N1)v and from 23 HIV-positive and six HIV-
negative asymptomatic controls were analyzed to evaluate the clinical picture, A(H1N1)v viral shedding, and the immune response against 
the virus. 
Results: Patients displayed mainly upper respiratory tract diseases (57.1%), while pneumonia was diagnosed only in HIV-negative patients 
(23.8% of subjects, of which 4.8% required intensive care unit admission). At day seven, 29% of HIV-infected patients were still positive for 
A(H1N1)v by RT-PCR on nasopharyngeal swabs. Interestingly, a persistence of CXCL10 secretion at high level and lower IL-6 levels was 
observed in HIV-positive subjects. The geometric mean haemagglutination inhibition titer (HI-GMT) and anti-influenza IgM levels were 
lower in HIV-positive individuals while anti-influenza IgG levels remained similar in the two groups. 
Conclusions: The immune impairment due to HIV infection could affect A(H1N1)v clearance and could lead to a lower antibody response 
and a persistent secretion of CXCL10 at high levels. However, the lower IL-6 secretion and treatment with highly active antiretroviral 
therapy (HAART) could result in a milder clinical picture. 
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Introduction 
On 11 June 2009, the World Health Organization 
(WHO) gave a pandemic alert in response to the 
global spread of a novel influenza virus. Since the first 
human case of infection, the novel pandemic influenza 
A (H1N1) virus, then named influenza A (H1N1)v 
virus, rapidly spread in US and Mexico, leading to 
global transmission through Europe [1]. The new virus 
was the result of a triple reassortment that combined 
gene segments from the North America and Eurasian 
swine H1N1 lineage; its historical origin can be 
located in 1918, when a virus of avian origin infected 
humans, causing the Spanish flu outbreak [2]. The 
distinctive combination of gene segments gives 
(H1N1)v antigenic features that make it dissimilar 
from seasonal influenza A [3].  
The function of host immune response to 
eliminating (H1N1)v or the role of host immune 
response in contributing to respiratory illness of 
(H1N1)v infections is not clear. Studies on SARS CoV 
and influenza A (H5N1) have previously identified 
specific host immune signatures [4]. These studies also 
included (H1N1)v and showed that in the early phase 
of the infection, most of the mild outcomes are 
characterized by the expression of systemic levels of 
chemokines, such as CXCL10, that are associated with 
the innate antiviral response [5]. 
Although (H1N1)v generally leads to mild 
infection symptoms, thousands of deaths have been 
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reported from the first confirmed case [1], mostly 
associated with patients with underlying risk factors 
that are known to contribute to a severe outcome, such 
as metabolic dysfunctions, pregnancy, and 
immunodeficiency [6]. Indeed, reports from Africa 
have shown that a high proportion of fatal cases of 
(H1N1)v occurred in HIV-infected people with 
advanced disease and none under highly active 
antiretroviral therapy (HAART) [7]. Hence, HIV 
infection is a possible risk factor for severe (H1N1)v 
outcome because it is associated with deficiencies in 
humoral and cell-mediated immunity that is reflected 
in an impaired development and maintenance of 
serological memory [8]. Moreover, as a result of HIV 
infection, T cell depletion might aggravate the clinical 
outcome, resulting in an extended length of influenza 
infection [9].  
Even if influenza is a common cause of respiratory 
illness among the HIV-positive population, limited 
data are available on the clinical course of influenza in 
this group of people; in this context, the 2009 (H1N1)v 
pandemic provided a unique opportunity for 
investigation. To determine if HIV-infected patients 
are able to clear the (H1N1)v infection, a cohort of 
HIV-positive patients infected with the 2009 pandemic 
influenza A virus was monitored; the study focused on 
the impact of infection on the innate and humoral 
immune responses. The hemagglutination inhibition 
assay (HI) was used to evaluate patients’ ability to 
generate antibodies against the (H1N1)v, and 
characterization of the innate immune signatures was 
assessed by measuring cytokine and chemokine 
secretions associated with the development of the 
adaptive immunity in relation to HIV infection. The 
results of this study identified a specific hallmark 
characterizing the host immune response of HIV-




During the 2009-2010 season, a prospective 
observational study was performed at the Agostino 
Gemelli Hospital, a reference University Hospital in 
Rome, Italy. All adults and adolescents seeking 
medical care for influenza-like illnesses (ILI) were 
enrolled. The main aim of the study was to describe 
clinical features of influenza A (H1N1)v virus 
infection (detailed study design and clinical results are 
published elsewhere) [10]. At the time of first medical 
evaluation (day 0), nasopharyngeal swabs and serum 
samples were obtained from each subject and sent for 
virological analyses. For the subgroups of HIV-
positive and HIV-negative patients testing positive for 
influenza A(H1N1)v virus by real time reverse 
transcriptase polymerase chain reaction (RT-PCR), 
nasopharyngeal swabs and serum samples were 
collected at seven and 14 days after the first sample 
was collected. Nasopharyngeal swabs and serum 
samples were also collected from a control group of 
asymptomatic HIV-positive and HIV-negative patients 
who did not have a referred episode of ILI in the 
previous month.  
For all patients, demographic and clinical data 
were collected using a pre-defined form. The evolution 
of symptoms was then recorded until recovery by 
reviewing medical charts (for hospitalized patients) 
and by outpatient visits or telephone medical 
interviews (for discharged patients).  
 
Viral diagnosis 
Nasopharyngeal swabs were immediately sent for 
microbiological analysis. A 400-µL aliquot of the 
specimen was used for automated RNA extraction 
with an EZ1 viral kit (QIAGEN, Hilden, Germany) 
and then subjected to real time RTPCR. Primers and 
probes for the H1 gene (swH1) and M gene (InfA) 
used in this work were recommended by the WHO 
[11] and were synthesized by Applied Biosystems 
(Forest City, USA). RT-PCR was performed in a 
25 μL reaction volume that contained 5 μl of the RNA 
dilution, 12.5 μl 2x AgPath-ID One-Step RT-PCR 
buffer, 1  μL enzyme mix, 0.5 μL assay mix in a 
fluorometric PCR instrument (ABI 7300). Thermal 
cycling conditions were 30 minutes at 50°C followed 
by 10 minutes at 95°C and a subsequent 45 cycle 
amplification (95°C for 15 seconds, 55°C for 30 
seconds; fluorescence was collected at 55°C). 
 
Cytokine and chemokine quantification 
Serum samples obtained at each time point were 
stored at -80°C until analyses were performed. To 
evaluate the immune response profile during (H1N1)v 
infection, samples obtained at each time point (day 0, 
7, and 14) from HIV-positive or HIV-negative 
(H1N1)v-infected patients and from their 
corresponding controls (HIV-positive or HIV-negative 
(H1N1)v-uninfected patients) were tested to determine 
levels of cytokines and chemokines (CXCL10, CCL-2, 
CXCL9, CXCL8, IL-17, IFN-γ, IL-10, IL-6, IL-4, IL-
2,IL-12p70, TNF α, IL-1β). Serum chemokine and 
cytokine levels were evaluated by flow cytometry 
using BD Cytometric Bead Array (CBA) human 
inflammatory cytokines and Th1/Th2/Th17 human 
cytokines kit. 
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Hemagglutination inhibition assay (HI) 
To evaluate antibody response against (H1N1)v, 
hemagglutination inhibition (HI) assay was performed 
on sera collected at day 0 and 14. Sera were treated 
with receptor-destroying enzyme (RDE-Sigma) of V. 
cholera by diluting one part serum with four parts of 
the enzyme and were incubated overnight in a 37°C 
water bath. The enzyme was inactivated by a 30-
minute incubation at 56°C followed by the addition of 
three volumes of sodium citrate 2.5 % for a final 
dilution of 1/10. HI assays were performed in V-
bottom 96-well microtiter plates with 0.5% chicken 
erythrocytes, as previously described, [12] using 




To further investigate the expression of class-
specific IgM and IgG antibodies during (H1N1)v 
infection, a modified enzyme-linked immunosorbent 
assay (ELISA) protocol was performed as described 
previously [13]. Briefly, BPL-California/07/09 H1N1 
virus (adjusted to 20 hemagglutination units/well in 
PBS) was used as a coating antigen. Plates were 
blocked with PBS containing 1% BSA and incubated 
for 1 hour at 37°C. Serial dilutions of each human 
serum sample in PBS were added to the plates and 
incubated for two hours at room temperature. Bound 
antibodies were detected with goat anti-human IgG or 
IgM, and conjugated with horseradish peroxides 
(AbCam). Plates were stained with o-
Phenylenediaminedihydrochloride (OPD, Sigma 
Aldrich, Saint Louis, USA) in 0.05 M citrate-
phosphate buffer pH 5 (Sigma) as a substrate, and the 
absorbance was measured (wavelength, 492 nm) after 
stopping the reaction with 3 M H2SO4 solution.  
 
Statistical analysis 
Data analysis was performed using SPSS version 
15.0. Categorical variables were compared between 
groups using the Chi-square test or Fisher’s exact test, 
as appropriate; for continuous variables, comparisons 
were based on the non-parametric Mann-Whitney U 
test. GMT was compared by means of Student’s t test 
on the log10-transformed titers. A two-sided p value 
of less than 0.05 was considered statistically 
significant. 
 
Table 1: Patient cohort description 
    
Total patients (N=21) 
Etiology 









Male sex   10 (47.6) 3 (42.9) 
 
7 (50) 1.000 
Age (years)a 44 (38-49) 40 (31-49) 
 
44 (41-53) 0.263 
Smokers 2 (9.5) 1 (14.3) 
 
1 (7.1) 1.000 
Co-morbidities 
    
 
 
Cardiac Disease 3 (14.3) 0 (0) 
 
3 (21.4) 0.521 
 
Diabetes 2 (9.5) 0 (0) 
 
2 (14.3) 0.533 
 
Hypertension 3 (14.3) 0 (0) 
 
3 (21.4) 0.521 
 
Obesity 1 (4.8) 1 (14.3) 
 
0 (0) 0.333 
Epidemiological contact with confirmed or suspected 




Receipt of seasonal trivalent influenza vaccine 3 (14.3) 1 (14.3) 
 
2 (14.3) 1.000 
Diagnosis: 
    
 
 
Upper respiratory tract infection 12 (57.1) 5 (71.4) 
 
7 (50) 0.642 
 
Bronchitis 4 (19.0) 2 (28.6) 
 
2 (14.3) 574 
 
Pneumonia 5 (23.8) 0 (0) 
 
5 (35.7) 0.123 
Complications: 
    
 
 
Hospitalization 7 (33.3) 1 (14.3) 
 
6 (42.9) 0.337 
 
Lenght of hospitalization (days)a 7 (4-14) 7 (7-7) 
 
9 (3-14) 1.000 
 
Intensive Care Unit admission 1 (4.8) 0 (0) 
 
1 (7.1) 1.000 
 
Oxygen supplementation requirement 1 (4.8) 0 (0) 
 
1 (7.1) 1.000 
Therapy: 
     
 
 
Oseltamivir 15 (71.4) 7 (100) 
 
8 (57.1) 0.061 
  Antibiotics 13 (61.9) 3 (42.9)   10 (71.4) 0.346 
Notes: values are expressed as n (%) except for a median (interquartile range); bcomparisons are based on Chi square test or Student’s t test.  
Abbreviations: COPD, chronic obstructive pulmonary disease; C-PAP, continuous positive airway pressure. 
None of the subjects received Influenza A (H1N1) 2009 monovalent Vaccine. 
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Results 
Description of patient cohort and (H1N1)v infection 
Complete clinical data, nasopharyngeal swabs, and 
serum samples at each time point (day 0, 7, and 14) 
were available for a total of 21 (H1N1)v-infected (7 
HIV-positive and 14 HIV-negative) patients. All 
subjects were enrolled during the second wave of the 
(H1N1)v pandemic in the fall between October and 
December of 2009. The main demographical and 
clinical characteristics are shown in Table 1. Subjects 
were mainly young adults with classic ILI symptoms. 
All patients (HIV positive and HIV negative) were 
mainly affected by upper respiratory tract diseases 
(57.1%), while pneumonia was diagnosed only in 
HIV-negative individuals (23.8% of subjects, of which 
4.8% required intensive care unit admission and four 
of five were treated with oseltamivir). Hospitalization 
occurred in 33.3% of patients; the median length of 
hospitalization was seven days (interquartile range 
(IQR) 4-14). HIV-positive patients had a median value 
for CD4 and CD8 cells count of 637 cell/mm3 (IQR 
373-757) and 775 cell/mm3 (IQR 637-1115), 
respectively; six of seven (86%) were enrolled in 
combined antiretroviral therapy, and all seven (100%) 
had a HIV RNA < 50 copies/mL. No statistically 
significant differences in the main demographical and 
clinical characteristics were observed between HIV-
infected and uninfected patients (Table 1).  
Seven days following the first diagnosis, as 
assessed by RT-PCR, all HIV-uninfected patients were 
negative for (H1N1)v, while 29% (n = 2) of HIV-
infected patients were still positive for (H1N1)v (p = 
0.100). At day 14, all patients (HIV-positive and 
negative) tested negative for (H1N1)v and were free of 
any disease symptoms.  
To compare the basal immune profile in the 
absence of (H1N1)v infection, a control group of 29 
asymptomatic (H1N1)v-uninfected patients (23 HIV 
positive and six HIV negative) with available serum 
samples was also included in the study. 
 
Comparison of immune markers expression between 
(H1N1)v-infected and uninfected patients  
The levels of the immune markers, cytokines, and 
chemokines were evaluated in serum samples by flow 
cytometry analysis using the CBA assay as a standard 
method.  
  
Figure 1. Immune marker expressions in HIV-negative and 
HIV-positive (H1N1)v-infected patients 
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In HIV-negative patients, an increase of the 
chemokines CXCL10 (p = 0.003), CXCL8 (p = 0.005) 
and the cytokines IFNγ (p = 0.01), IL-10 (p = 0.002), 
IL-6 (p = 0.002), and IL-1β (p = 0.01) was observed 
during the acute phase of (H1N1)v infection (day 0) 
when compared to healthy controls (HIV-negative, 
(H1N1)v-uninfected). Moreover, whereas CXCL10 (p 
= 0.2), IFNγ (p = 0.3), and IL-10 (p = 0.1) returned to 
a basal level at day 7, CXCL8 (day 7, p - = 0.01; day 
14, p - 0.004), IL-6 (day 7, p = 0.01; day 14, p = 0.02) 
and IL-1β (day 7, p = 0.003; day 14, p = 0.02) 
remained high later on (day 14), when compared to 
healthy controls (Figure 1A to I) (Table 
Supplementary 1).  
In HIV-positive (H1N1)v-infected patients, 
significantly higher levels of CXCL10 (p = 0.02), 
CXCL9 (p = 0.01), IFNγ (p = 0.0004), IL-10 (p = 
0.01), IL-6 (p = 0.003),  IL-1β (p = 0.03), IL-17 (p = 
0.01), and IL-4 (p = 0.04) were observed compared to 
their corresponding controls (HIV-positive and 
(H1N1)v-uninfected) at day 0. While most of these 
cytokines returned to a basal level seven days 
following the first diagnosis, CXCL10 (p = 0.02) and 
(CXCL9 p = 0.03) still remained at higher levels in 
(H1N1)v-infected patients compared to their 
corresponding controls. In the late phase of infection 
(day 14) CXCL9 (p = 0.2) returned to a basal level, 
whereas CXCL10 (p = 0.02) remained at higher levels 
in the (H1N1)v-infected patients (Figure 1 L to T) 
(Table Supplementary 1). 
 
Comparison of immune markers expression between 
HIV-positive and HIV-negative (H1N1)v-infected 
patients  
A comparative analysis was performed to evaluate 
the differential secretion of cytokine and chemokine 
levels in HIV-positive and HIV-negative (H1N1)v-
infected individuals.  
During the acute phase (day 0) of infection, the 
serum cytokines levels appeared to be elevated in both 
HIV-positive and HIV-negative cohorts compared to 
their corresponding (H1N1)v negative controls (Figure 
1 L to T and A to I), though significant differences in 
the expression levels of immune mediators among 
these two groups of (H1N1)v-infected patients were 
not observed (Table Supplementary 1). 
Conversely, 7 and 14 days following the first 
diagnosis, significantly higher levels of CXCL10 were 
observed in the HIV-positive group compared to the 
HIV-negative cohort (day 7, p = 0.04; day 14, p = 
0.03) (Figure 2). Higher levels of CXCL10 observed 
in HIV-positive patients infected with (H1N1)v seems 
not to be ascribable to oseltamivir treatment, as 
demonstrated by the analysis comparingCXCL10 
levels in oseltamivir treated HIV-negative against 
HIV-positive patients (Figure Supplementary 1). Such 
analysis confirmed that increased CXCL10 expression 
by HIV-positive (H1N1)v-infected patients was not 
due to oseltamivir treatment, since HIV-positive 
patients maintained high levels of CXCL10 
expression, while the CLCL10 levels in HIV-
negative/(H1N1)v patients treated with oseltamivir 
decreased after 7 days of treatment. IL-6 expression 
was further analyzed comparing HIV-negative and 
HIV-positive patients treated with oseltamivir, 
confirming that antiviral therapy does not statistically 
influence immune mediators levels in HIV-negative 
patients treated with oseltamivir. Oseltamivir 
treatment lead to a strong decrease of the immune 
mediators in the HIV-negative group 7 days after 
administration. Conversely, in the HIV-positive 
patients, the level of CXCL10 remained higher. 
Although there was a decrease in statistical 
significance at day 7 (p = 0.18) when only the 
oseltamivir treated patients were compared, the HIV-
positive cohort had a delay in the normalization of 
CXCL10 levels compared to the HIV-negative cohort 
as the higher levels at day 14 show (p < 0.05) (Figure 
Supplementary 1). 
 
Assessment of differential basal expression of immune 
mediators in HIV-positive and HIV-negative (H1N1)v-
uninfected control subjects  
To determine whether the differential basal levels 
of cytokine expression observed were the results of 
HIV infection, serum samples from HIV-negative and 
HIV-positive asymptomatic (H1N1)v-uninfected 
patients were analyzed. Most of the cytokines tested 
Figure 2. Level of CXCL10 in HIV-positive and HIV-negative 
patients 
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were found at similar levels in the two groups, though 
in HIV-positive patients, higher levels of IL-6 (p = 
0.02), IL-1β (p = 0.04), and CXCL8 (p = 0.02) were 
detected compared to the HIV-negative individuals 
(Figure 3) (Table Supplementary 2). To determine 
whether this observation could have been influenced 
by oseltamivir treatment, oseltamivir-treated HIV-
negative/(H1N1)v patients were compared to the HIV-
positive/(H1N1)v cohort (Figure Supplementary 2). 
This analysis showed that the higher IL-6 basal level 
was not influenced by oseltamivir treatment. 
The low influence of oseltamivir treatment on this 
analysis was further confirmed by the analysis of HIV-
negative/(H1N1)v treated or untreated patients with 
the antiviral-treated patients (Figure 2). As shown by 
bar graphs, none of the cytokines analyzed were 
significantly different between the treated and 
untreated groups. Only a difference on day 0 was seen 
for CXCL10 and IL-6 in HIV-negative/(H1N1)v 
patients who were then treated with oseltamivir 
because they developed strong symptoms and the 
antiviral therapy was then supplied. 
Finally, in order to exclude that these observations 
could have been influenced by comorbidities in the 
HIV-negative/(H1N1)v cohort, an analysis was 
performed, excluding from this group the patients with 
other diseases specified in Table 1. Such analysis 
confirmed that, even excluding comorbidities, the 
difference between CXCL10 and IL-6 expression in 
HIV-positive and HIV-negative (H1N1)v-infected 
patients remains statistically significant (Figure 3). 
 
Comparison of antibody response between HIV-
infected and uninfected patients  
To evaluate antibody response against (H1N1)v, 
an HI assay was performed on sera obtained from 
HIV-positive and HIV-negative (H1N1)v-infected 
individuals at day 0 and day 14. In HIV-negative 
patients, the geometric mean titer (GMT) significantly 
increased over time from 22.08 at day 0 (95% 
confidence intervals (CI) 10.60-45.99) to 204.9 at day 
14 (95% confidence intervals (CI) 112.5-373; p = 
0.006) and in the same time frame also in HIV-
positive patients from 14.96 at day 0 (95% confidence 
intervals (CI) 7.183-30.74) to 107.7 at day 14 (95% 
confidence intervals (CI) 47.63-243.4; p = 0.02).   
 
While an increase in IgM secretion was observed 
in both HIV-positive and HIV-negative patients, at day 
14, a significantly higher level of IgM was observed in 
HIV-negative patients (p = 0.004) (Figure 4A). A 
similar pattern was observed for IgG, though HIV-
negative subjects showed a significantly higher level 
of IgG at day 0 compared to their HIV-positive 
counterparts (p = 0.045) (Figure 4B). 
 
Discussion 
The pandemic spread of the novel influenza virus 
has raised concerns on the possible increased risk of 
severe infection in immune-suppressed populations. 
As it has already been shown, the 2009 (H1N1)v 
infection seems to be associated with mild clinical 
outcomes. Nevertheless, experiments conducted in 
animal models indicated that (H1N1)v infection may 
result in more severe lung lesions in humans compared 
to mice, ferrets, and non-human primates infected with 
the seasonal human H1N1 virus [14], suggesting that 
(H1N1)v can cause distinctive clinical effects, 
especially in patients with a compromised immune 
system [15]. HIV infection, which is associated with 
anomalous humoral and T-cell–mediated immune 
responses, could result in increased susceptibility to 
viral respiratory infections [16]. However, recent 
studies have reported that the susceptibility of HIV-
infected patients without advanced disease to 2009 
H1N1v influenza may not be increased [17].  
Figure 4. IgG and IgM response between HIV-infected and 
HIV-uninfected patients 
Figure 3. Cytokine levels in HIV-negative and HIV-positive 
(H1N1)v-uninfected patients 
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Here, we investigated the clinical outcomes 
following (H1N1)v infection in HIV-positive and 
HIV-negative patients and attempted to identify the 
immune signatures associated with the two groups. We 
found that (H1N1)v infection presents different 
clinical outcomes in HIV-positive compared to HIV-
negative patients, and that this relates to a different 
immune response in these two groups.  
In this study, the clinical picture following 
(H1N1)v-infection in HIV-positive patients appeared 
milder overall compared to what was observed in 
HIV-negative subjects. In fact, cases of severe 
complications with onset of pneumonia that led to 
hospitalization and that, in one case, required oxygen 
supplementation, were detected only in HIV-negative 
patients. This is in apparent contrast with previous 
findings, where no remarkable differences in clinical 
outcomes were observed in HIV-positive patients 
compared to HIV-negative subjects [18,19]. In a study 
by Peters et al., 911 subjects were analyzed in three 
separate cohorts, which included HIV+ patients with 
CD4 counts below 200, with half taking ART. The 
results of the study showed that receiving ART 
approximates significance in terms of being admitted 
to an ICU and/or death. The majority of the patients 
receiving ART therapy were HIV-infected patients 
with a CD4 cell count <200 cells/µL, while in the 
present study, the median value for CD4 counts was 
more than 600; this could explain the differences in 
the findings [20]. 
However, other studies have shown that influenza 
infection in HIV-positive subjects usually has a milder 
outcome, probably as a result of the immune 
impairment due to CD4-deficiency [21]. Indeed, it has 
been shown that complications following influenza 
infection result from an inflammatory burst triggered 
by a cytokine and chemokine storm induced by viral 
replication in the lung parenchyma, which directly 
involves CD4 T cells [22].   
To determine whether the different clinical 
outcomes observed among HIV-positive and HIV-
negative patients were dependent upon a diverse 
immune response, we dissected the immune response 
elicited following (H1N1)v infection using the human 
beads cytokines array assay (CBA, BD). With this 
method we were able to detect and quantify different 
chemokines, cytokines, and immune mediators 
through flow cytometry analysis in the serum of 
(H1N1)v infected patients and controls.  
Interestingly, HIV-positive patients did not show 
remarkable differences in the cytokine and chemokine 
patterns in response to H1N1 infection compared to 
HIV-negative patients, although the chemokine 
CXCL10 appeared elevated along the time of the 
infection in the HIV-positive group, showing a delay 
in the long-term normalization of its level compared to 
what was reported in HIV-negative patients. CXCL10 
or IP-10 is an IFN-γ-inducible protein that plays an 
important role in the host response to a diversity of 
viral infections [23]; it is expressed in a variety of cells 
in response to IFN-γ stimulation [24]. High levels of 
CXCL10 have been associated with a poor control of 
viral infection by the immune system [25,4].Moreover, 
increased levels of CXCL10 on plasma have been 
already detected by Kamat et al. in HIV patients on 
HAART [26]. Hence, the immune dysfunction during 
HIV infection mainly reflected in the CD4 T cell 
impairment could lead to a persistent secretion of 
CXCL10 at high levels, as observed in HIV-positive 
patients. 
Another interesting observation comes from the 
analysis of IL-6 that was found to be lower in HIV-
positive compared to HIV-negative patients. The 
higher secretion of IL-6, which is considered an 
activator of the acute phase responses [27] and also a 
marker of critical illness during influenza infection 
[28,5], may also explain the more severe clinical 
outcomes reported in HIV-negative patients, 
supporting the hypothesis that clinical complications 
following influenza infection may result from an 
inflammatory burst. It was shown that higher levels of 
IL-6 in pre-HAART HIV patients correlate with 
higher morbidity and mortality rates [29]. These data 
suggest that IL-6 can effectively be considered as a 
valuable marker of severe infection.  
Protection and viral clearance during influenza 
infection relies on the humoral arm of the immune 
response. To determine the H1N1v serum antibody 
levels, the GMT level in HIV-positive and negative 
patients at day 0 and day 14 of the H1N1 infection 
were analyzed. While HIV-positive patients were able 
to mount an effective antibody response, they showed 
a significantly lower GMT at day 14 compared to 
HIV-negative patients. Interestingly, the difference in 
GMT observed was dependent on the impairment of 
HIV-positive subjects to mount a solid IgM response, 
since IgG levels were similar among the two groups. 
While the immunological basis of the difference 
between IgG and IgM response remains unknown, it is 
of interest to note that IgMs are known to be highly 
neutralizing and may contribute to viral clearance. The 
reduced viral clearance observed in the HIV-positive 
group may result from the impaired ability to mount 
an IgM response. 
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However, our data consider HIV-infected patients 
to be in a no-advance immune suppression, as the 
CD4+ and CD8+ cell counts show (CD4+ > 200 
cells/mm3 and CD8+ < 1000 cells/mm3), and under 
HAART, which reduces the incidence of opportunistic 
infection; this suggests that influenza severity could be 
different in a situation of advanced HIV disease or in 
the presence of comorbidities. Furthermore, it should 
be taken into account that HAART is not accessible to 
HIV-infected people in many parts of the world, 
especially in developing countries, where pulmonary 
complications of HIV infection are major causes of 
morbidity and mortality [9]. 
In summary, HIV-infected patients under HAART 
show a distinctive feature in the immune response 
against 2009 pandemic influenza, characterized by a 
persistent secretion of high levels of CXCL10 and 
lower antibody responses. It may be hypothesized that 
the immune impairment due to the HIV infection in 
patients under HAART could lead to a higher 
CXCL10 secretion at long term, and to a delay in 
normalization of its levels during recovery. Moreover, 
the poorer response of specific antibodies thus 
potentially affects virus clearance. Nonetheless, the 
concomitant lower IL-6 secretion, which has been 
described to be associated with critical illness during 
influenza infection [27,30], could explain the milder 
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Table Supplementary 1: Median and interquartile range for chemokines and cytokines in HIV-infected and HIV-uninfected 
(H1N1)v-positive patients 






Day 0 712,35 2.386 
CXCL10 
Day 0 1860,5 4.796 
Day 7 1050,8 4.201 Day 7 533 2.451 
Day 14 780,7 491 Day 14 365 2.168 
CCL2 
Day 0 809 839 
CCL2 
Day 0 486 2.565 
Day 7 764 1.352 Day 7 477 836 
Day 14 375 582 Day 14 479 692 
CXCL9 
Day 0 567,25 1.952 
CXCL9 
Day 0 403 1.107 
Day 7 693,1 1.234 Day 7 231 2.023 
Day 14 418 739 Day 14 235 2.688 
IL-17 
Day 0 12,9 11 
IL-17 
Day 0 10 10 
Day 7 11 4 Day 7 10 29 
Day 14 9 7 Day 14 10 7 
INFɣ 
Day 0 15,4 20 
INFɣ 
Day 0 16,85 352 
Day 7 4 5 Day 7 4 15 
Day 14 4 4 Day 14 4 17 
IL-10 
Day 0 3,7 24 
IL-10 
Day 0 4,8 54 
Day 7 2 24 Day 7 4 7 
Day 14 0 2 Day 14 3 15 
IL-4 
Day 0 2,9 4 
IL-4 
Day 0 2 4 
Day 7 2 4 Day 7 2 13 
Day 14 2 3 Day 14 2 3 
IL-2 
Day 0 4 6 
IL-2 
Day 0 4 5 
Day 7 4 1 Day 7 4 9 
Day 14 4 1 Day 14 3 2 
IL-12p70 
Day 0 3 37 
IL-12p70 
Day 0 2 48 
Day 7 3 32 Day 7 2 40 
Day 14 3 77 Day 14 2 198 
TNFα 
Day 0 0 1 
TNFα 
Day 0 0 4 
Day 7 0 2 Day 7 0 2 
Day 14 1 3 Day 14 0 9 
IL-6 
Day 0 9,9 23 
IL-6 
Day 0 25,2 171 
Day 7 5 15 Day 7 4,95 51 
Day 14 4 33 Day 14 5,8 104 
IL1-β 
Day 0 11,08 92 
IL1-β 
Day 0 20,2 114 
Day 7 9 17 Day 7 11,8 61 
Day 14 6 48 Day 14 11,6 73 
CXCL8 
Day 0 36 41 
CXCL8 
Day 0 29,6 556 
Day 7 31 41 Day 7 23,45 223 
Day 14 31 134 Day 14 42,6 141 
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Table Supplementary 2: Median and interquartile range for chemokines and cytokines for asymptomatic control patients 





CXCL10 480 860 CXCL10 457 235 
CCL2 371 806 CCL2 341 393 
CXCL9 214 1.145 CXCL9 144 872 
IL-17 10 28 IL-17 12 4 
INFɣ 4 15 INFɣ 4 3 
IL-10 0 11 IL-10 3 2 
IL-4 2 6 IL-4 2 3 
IL-2 3 6 IL-2 3 1 
IL-12p70 3 632 IL-12p70 0 8 
TNFα 0 38 TNFα 0 0 
IL-6 4 343 IL-6 0 4 
IL1-β 3 114 IL1-β 0 2 





Figure Supplementary 1. Cytokine levels for CXCL10 (A) and IL6 (B) in oseltamivir-treated HIV-negative and HIV-positive (H1N1)v-
infected patients at day 0, 7, and 14 following diagnosis  
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Figure Supplementary 2. Cytokine levels in oseltamivir-treated (-) and oseltamivir-untreated (-) HIV-negative (H1N1)v-infected patients at 




Figure Supplementary 3. Cytokine levels excluding HIV-negative patients with underlying comorbidities, for CXCL10 (A) and IL6 (C) in 
HIV-positive and HIV-negative (H1N1)v-infected patients at day 0, 7 and 14 following diagnosis  
*Significant difference p < 0.05 
 
